Quercetin-4′-o-β-d-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Lin, Chen ^a   Wu, Menghua ^a   Dong, Jianyong ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONOID; FOCAL ADHESION KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; QUERCETIN 4' O BETA DEXTRO GLUCOPYRANOSIDE; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; GLUCOSIDE; QUERCETIN; QUERCETIN 4' O GLUCOPYRANOSIDE; QUERCETIN 4'-O-GLUCOPYRANOSIDE;

AMPUTATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY PROLIFERATION; CELL MOTILITY; CELL VIABILITY; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; FERTILIZATION; HUMAN; HUMAN CELL; HYPERICUM; HYPERICUM ATTENUATUM; IN VIVO STUDY; MORPHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; DRUG EFFECT; HERBAL MEDICINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION;

DANIO RERIO; HYPERICUM ATTENUATUM;

ANGIOGENESIS INHIBITORS; ANIMALS; GLUCOSIDES; HERBAL MEDICINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; QUERCETIN; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

EID: 84863167579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031708     Document Type: Article

References (118)

1. Quesada AR, Muñoz-Chápuli R, Medina MA, (2006) Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26: 483-530.
2. Carmeliet P, (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
3. Folkman J, (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
4. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, et al. (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for anti-angiogenic tumor therapies. Cancer Res 60: 1388-1393.
5. Compagni A, Christofori G, (2000) Recent advances in research on multistage tumorigenesis. Br J Cancer 83: 1-5.
6. Ferrara N, Kerbel RS, (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.
7. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
8. Zhong H, Bowen JP, (2007) Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 7: 1379-1393.
9. Ferrara N, (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
10. Folkman J, (1974) Tumor angiogenesis factor. Cancer Res 34: 2109-2113.
11. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
12. Dong DF, Li EX, Wang JB, Wu YY, Shi F, et al. (2009) Anti-angiogenesis and anti-tumor effects of AdNT4-anginex. Cancer Lett 285: 218-224.
13. Hanhan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigensis. Cell 86: 353-364.
14. Simó R, Carrasco E, García-Ramírez M, Hernández C, (2006) Angiogenic and anti-angiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98.
15. Ferrara N, (2002) VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2: 795-803.
16. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG, (2000) Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046-2052.
17. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, et al. (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61: 5407-5414.
18. Petrova TV, Makinen T, Alitalo K, (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253: 117-130.
19. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, et al. (1995) A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10: 135-147.
20. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, et al. (2000) Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275: 10661-10672.
21. Shibuya M, Claesson-Welsh L, (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560.
22. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
23. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, et al. (2000) Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19: 4621-4631.
24. Schlessinger J, (2000) New roles for Src kinases in control of cell survival and angiogenesis. Cell 100: 293-296.
25. Qi JH, Claesson-Welsh L, (2001) VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 263: 173-182.
26. Zachary I, Gliki G, (2001) Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49: 568-581.
27. Cho CH, Lee CS, Chang M, Jang IH, Kim SJ, et al. (2004) Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am J Physiol Heart Circ Physiol 286: H1881-1888.
28. Kim BW, Choi M, Kim YS, Park H, Lee HR, et al. (2008) Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal 20: 714-725.
29. Viñals F, Chambard JC, Pouysségur J, (1999) p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 274: 26776-26782.
30. Ferrara N, (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9: 2-10.
31. Kerbel RS, Kamen BA, (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.
32. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 99: 11393-11398.
33. Noble MEM, Endicott JA, Johnson LN, (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1805.
34. Kamba T, McDonald DM, (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795.
35. Spiekermann K, Faber F, Voswinckel R, Hiddemann W, (2002) The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 30: 767-773.
36. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 62: 4645-4655.
37. DeFeudis FV, Papadopoulos V, Drieu K, (2003) Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 17: 405-417.
38. Büchler P, Reber HA, Büchler MW, Friess H, Lavey RS, et al. (2004) Anti-angiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and down-regulation of VEGF gene expression. Cancer 100: 201-210.
39. Martínez-Poveda B, Quesada AR, Medina MA, (2005) Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Int J Cancer 117: 775-780.
40. Donà M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, et al. (2004) Hyperforin Inhibits Cancer Invasion and Metastasis. Cancer Res 64: 6225-6232.
41. Schempp CM, Kiss J, Kirkin V, Averbeck M, Simon-Haarhaus B, et al. (2005) Hyperforin acts as an angiogenesis inhibitor. Planta Med 71: 999-1004.
42. Makovets'ka OIu, (2000) Biologically active substances isolated from Hypericum attenuatum Choisy. Ukr Biokhim Zh 72: 110-113.
43. Cheng SH, Han PK, Wu RS, (2001) The use of microangiography in detecting aberrant vasculature in zebrafish embryos exposed to cadmium. Aquat Toxicol 52: 61-71.
44. Peterson RT, Mably JD, Chen JN, Fishman MC, (2001) Convergence of distinct pathways to heart patterning revealed by the small molecule concentramide and the mutation heart-and-soul. Curr Biol 11: 1481-1491.
45. Ding LL, Liu M, Zhang SH, Zhao XZ, Wu N, et al. (2010) Lidamycin inhibits angiogenesis of zebrafish embryo via down-regulation of VEGF. Yao Xue Xue Bao 45: 456-461.
46. Nicoli S, De SG, Presta M, (2009) Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med 13: 2061-2068.
47. Zheng L, Ling P, Wang Z, Niu R, Hu C, et al. (2007) A novel polypeptide from shark cartilage with potent anti-angiogenic activity. Cancer Biol Ther 6: 775-780.
48. Wang Z, Zheng L, Yang S, Niu R, Chu E, et al. (2007) N-acetylchitooligosaccharide is a potent angiogenic inhibitor both in vivo and in vitro. Biochem Biophys Res Commun 357: 26-31.
49. Serbedzija GN, Flynn E, Willett CE, (1999) Zebrafish angiogenesis: a new model for drug screening. Angiogenesis 3: 353-359.
50. Lawson ND, Weinstein BM, (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248: 307-318.
51. Lawson ND, Weinstein BM, (2002) Arteries and veins: making a difference with zebrafish. Nat Rev Genet 3: 674-682.
52. Childs S, Chen JN, Garrity DM, Fishman MC, (2002) Patterning of angiogenesis in the zebrafish embryo. Development 129: 973-982.
53. Bayliss PE, Bellavance KL, Whitehead GG, Abrams JM, Aegerter S, et al. (2006) Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol 2: 265-273.
54. Huang CC, Wang TC, Lin BH, Wang YW, Johnson SL, et al. (2009) Collagen IX is required for the integrity of collagen II fibrils and the regulation of vascular plexus formation in zebrafish caudal fins. Dev Biol 332: 360-370.
55. Shibuya M, (2006) Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13: 63-69.
56. Patan S, (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32.
57. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954.
58. Klagsbrun M, D'Amore PA, (1996) Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7: 259-270.
59. Zachary I, (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280: C1375-1386.
60. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, et al. (2004) The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR1) modulates Flk-1 (VEGFR2) signaling during blood vessel formation. Am J Pathol 164: 1531-1535.
61. Lamalice L, Houle F, Huot J, (2006) Phosphorylation of Tyr1214 within VEGFR2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem 281: 34009-34020.
62. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, et al. (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24: 2342-2353.
63. Takahashi T, Yamaguchi S, Chida K, Shibuya M, (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778.
64. Ahmad S, Hewett PW, Al-Ani B, Sissaoui S, Fujisawa T, et al. (2011) Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell 3: 15.
65. Cunningham SA, Waxham MN, Arrate PM, Brock TA, (1995) Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 270: 20254-20257.
66. Sawano A, Takahashi T, Yamaguchi S, Shibuya M, (1997) The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. Biochem Biophys Res Commun 238: 487-491.
67. Ito N, Wernstedt C, Engström U, Claesson-Welsh L, (1998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 273: 23410-23418.
68. Takahashi T, Yamaguchi S, Chida K, Shibuya M, (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778.
69. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M, (2005) Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 102: 1076-1081.
70. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943.
71. Pang X, Yi Z, Zhang J, Lu B, Sung B, et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70: 1951-1959.
72. Edirisinghe I, Yang SR, Yao H, Rajendrasozhan S, Caito S, et al. (2008) VEGFR2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. FASEB J 22: 2297-2310.
73. Berger NA, Petzold SJ, (1985) Identification of minimal size requirements of DNA for activation of poly(ADP-ribose) polymerase. Biochemistry 24: 4352-4355.
74. Berger NA, (1985) Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 101: 4-15.
75. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG, (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985.
76. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
77. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
78. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, et al. (1996) Human ICE/CED-3 protease nomenclature. Cell 87: 171.
79. Cohen GM, (1997) Caspases: the executioners of apoptosis. Biochem J 326: 1-16.
80. Cryns V, Yuan J, (1998) Proteases to die for. Genes Dev 12: 1551-1570.
81. Le Rhun Y, Kirkland JB, Shah GM, (1998) Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 245: 1-10.
82. Kerbel R, Folkman J, (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
83. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP, (2009) Diabetic Retinopathy and Angiogenesis. Curr Diabetes Rev 5: 8-13.
84. Ren W, Qiao Z, Wang H, Zhu L, Zhang L, (2003) Flavonoids: promising anticancer agents. Med Res Rev 23: 519-534.
85. Aggarwal BB, Shishodia S, (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
86. Rousseau S, Houle F, Huot J, (2000) Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 10: 321-327.
87. Ferrara N, Gerver HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
88. Kowanetz M, Ferrara N, (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022.
89. Shibuya M, (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478.
90. Kanda S, Miyata Y, Kanetake H, Smithgall TE, (2007) Non-receptor protein-tyrosine kinases as molecular targets for anti-angiogenic therapy. Int J Mol Med 20: 113-121.
91. Chou MT, Wang J, Fujita DJ, (2002) Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem 3: 32.
92. Ali N, Yoshizumi M, Fujita Y, Izawa Y, Kanematsu Y, et al. (2005) A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci 98: 130-141.
93. Mitra SK, Schlaepfer DD, (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523.
94. Matsuo M, Yamada S, Koizumi K, Sakurai H, Saiki I, (2007) Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur J Cancer 43: 1748-1754.
95. Li W, Tan DF, Zhang ZP, Liang JJ, Brown RE, (2008) Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20: 713-719.
96. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, et al. (2008) Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14: 3589-3597.
97. García-Maceira P, Mateo J, (2009) Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signaling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28: 313-324.
98. Wouters BG, Koritzinsky M, (2008) Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864.
99. Liu B, Faia L, Hu M, Nussenblatt RB, (2010) Pro-angiogenic effect of IFNγ is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol Vis 16: 184-193.
100. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, et al. (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516.
101. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M, (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27-34.
102. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C, (1994) Macrophages and angiogenesis. J Leukoc Biol 55: 410-422.
103. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, et al. (1997) Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 3: 2187-2190.
104. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, et al. (1995) Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270: 12607-12613.
105. Iijima K, Yoshikawa N, Connolly DT, Nakamura H, (1993) Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 44: 959-966.
106. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, et al. (1995) Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 203: 80-92.
107. Tufro A, Norwood VF, Carey RM, Gomez RA, (1999) Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 10: 2125-2134.
108. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, et al. (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628.
109. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1998) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
110. Chintalgattu V, Nair DM, Katwa LC, (2003) Cardiac myofibroblasts: A novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol 35: 277-286.
111. Reichardt LF, Tomaselli KJ, (1991) Extracellular matrix molecules and their receptors: Functions in neural development. Annu Rev Neurosci 14: 531-570.
112. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ, (2001) Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85: 273-278.
113. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM, (2002) Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J Cell Biol 158: 165-174.
114. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, et al. (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195.
115. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, et al. (1995) Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270: 28316-28324.
116. Plate KH, Breier G, Weich HA, Risau W, (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
117. Pang X, Yi T, Yi Z, Cho SG, Qu W, et al. (2009) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69: 518-525.
118. Tang JY, Li S, Li ZH, Zhang ZJ, Hu G, et al. (2010) Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 5: e11822.